[Market Focus] ENCell Surges on U.S. Patent Registration for Charcot-Marie-Tooth Disease Treatment Drug

ENCell is showing strong performance. This is believed to be due to the news that the company has registered a patent for a new drug for the prevention and treatment of Charcot-Marie-Tooth disease with the United States Patent and Trademark Office (USPTO).

As of 1:47 p.m. on the 16th, ENCell was trading at 17,570 won, up 21.17% from the previous day.

On this day, ENCell announced that a patent for the use of its next-generation stem cell therapy, EN001, for the treatment of Charcot-Marie-Tooth disease (CMT), has been officially registered with the USPTO.

The registered U.S. patent pertains to a "pharmaceutical composition for the prevention or treatment of Charcot-Marie-Tooth disease comprising mesenchymal stem cells or insulin secreted from mesenchymal stem cells." The patent holders are the Samsung Life Public Welfare Foundation and ENCell Co., Ltd., and the patent is valid until November 7, 2042.

CMT is an intractable genetic disorder caused by peripheral nerve damage, leading to deformities of the hands and feet, muscle atrophy, and loss of sensation. Although it is a rare disease, occurring in approximately 1 out of every 2,500 people, there is currently no fundamental cure, resulting in a very high level of unmet medical need worldwide.

This patent is the result of demonstrating that EN001, a mesenchymal stem cell produced using ENCell's proprietary ENCT (ENCell Technology), has an outstanding effect on nerve regeneration and muscle function recovery. In particular, it is significant that the insulin secreted by the stem cells promotes the proliferation of Schwann cells and regenerates damaged myelin sheaths, and that this new therapeutic mechanism has been granted exclusive rights in the U.S. market.

This content was produced with the assistance of AI translation services.